Voima and NSI, two Nordic-based deep tech and life science investors, served as the lead investors. The funding will be used to accelerate the technology development and commercialization of the company’s next-generation spatial transcriptomic technology.

“Biology is 3 dimensional. We want to enable measuring it in that way. We are thrilled to be backed by strong life science tech investors and the European innovation council that awarded our company for the high scalability and disruptiveness of our technology,” states Malte Kuhnemund, CEO.

CubaseBio

CubaseBio was founded in 2024 by Malte Kuhnemund, Xiaoyan Qian, Toon Verheyen and Paulius Mielinis. Amongst the scientific advisory co-founders are Joshua Weinstein (Assistant Professor of Molecular Engineering at UChicago) and Björn Högberg (Professor and head of the department Medical Biochemistry and Biophysics at the Karolinska Institute, Sweden).

CubaseBio‘s technology is based on the grounds built by Weinstein (UChicago) and researchers at the Karolinska Institute and KTH, Sweden – amongst Björn Högberg and Ian Hoffecker. Kuhnemund, Ph.D., and Qian, Ph.D., are former co-founders of CARTANA, a Scilifelab spinout that pioneered in situ sequencing, which was acquired by 10X Genomics in 2020 to form the foundation of the Xenium In Situ platform.